Three biologics targeting interleukin 5 (IL-5) or its receptor (IL-5Rα) are approved for use in patients with severe asthma. In a meta-analysis, Greek scientists have now investigated the clinical response to anti-IL-5/-5Rα biologics in real-world studies and provided insights into the use of these drugs in clinical practice.
Autoren
- Jens Dehn
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- Blastic plasmacytoid dendritic cell neoplasia
Rare malignancy from a dermatological perspective
- Psychooncology
Communication as the key to therapy adherence
- From symptom to diagnosis
Lung carcinoma – Pancoast tumor
- Deep vein thrombosis
Outpatient or inpatient treatment?
- From symptom to diagnosis
Abdominal pain – Intraductal papillary mucinous neoplasia
- IBDmatters - Advanced Therapeutic Treatments
Examinations and considerations before therapy
- “Swiss Health Care Atlas”
Supply situation in Switzerland at a glance
- Steatotic liver disease